Mylan EpiPen Antitrust $264M Class Action Settlement
“Mylan agreed to pay $264 million to resolve claims it worked with Pfizer and other companies to raise the cost of the EpiPen. The settlement benefits individuals and entities who paid for or provided reimbursement for branded EpiPens or generic equivalents between Aug. 24, 2011. EpiPens are used,” reports Top Class Actions in their blog.
“According to a 2017 class action lawsuit, Mylan may have worked with Pfizer to artificially raise the price of life saving EpiPen products. Plaintiffs in the class action lawsuit claimed the companies knowingly violated antitrust and racketeering laws through their scheme. Defendants devised an illegal scheme to monopolize the market.”
